Radiotherapy Delay After Lumpectomy Reduces Disease-Free Survival in Indigent Black Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 6
Volume 9
Issue 6

CHICAGO-Breast conservation followed by radiotherapy is an effective treatment approach for invasive breast cancer in medically indigent black women, but prompt initiation of the radiotherapy and adequate radiation dose are necessary to achieve optimal results, according to a study presented at the 85th Annual Meeting of the Radiological Society of North America (RSNA).

CHICAGO—Breast conservation followed by radiotherapy is an effective treatment approach for invasive breast cancer in medically indigent black women, but prompt initiation of the radiotherapy and adequate radiation dose are necessary to achieve optimal results, according to a study presented at the 85th Annual Meeting of the Radiological Society of North America (RSNA).

In this study, women who received radiotherapy within 30 days of lumpec-tomy had superior disease-free survival, compared with those in whom radiotherapy was delayed. Women who received a dose of at least 50 Gy achieved a greater degree of local control as well as longer disease-free and overall survival than those given lower doses, said Stuart H. Burri, MD, chief resident in Radiation Oncology, Emory University.

Dr. Burri and his colleagues reviewed the records of 88 black women who underwent breast-conservation therapy between 1980 and 1996 at Emory’s Grady Memorial Hospital. Most were uninsured or receiving Medicaid. Of these 88 women, 72 had invasive cancer: 56% stage I disease; 37.5% stage II; 5.6% stage III; and 33% had positive lymph nodes.

Following lumpectomy, radiotherapy was delivered to the involved breast by means of opposed tangents. The dose ranged from 45 to 55 Gy (median, 50 Gy), and 70% received a radiation boost (median dose, 10 Gy). Radiotherapy was delivered between 9 and 312 days after lumpectomy (median, 69 days). The average follow-up was 55.4 months.

The proportion of women with invasive breast cancer who had local control of their disease was 95% at 5 years and 88% at 10 years. Disease-free survival was 85% at 5 years and 65% at 10 years, and overall survival was 77% at 5 years and 43% at 10 years.

Local control, disease-free survival, and overall survival were inferior among women who received a radiotherapy dose to the tumor bed of less than 50 Gy (P < .0001). Treatment failure was more likely if radiotherapy was delayed for more than 30 days after lumpectomy (P = .0479).

Dr. Burri explained that the method of notifying patients of the need for radiotherapy was most likely responsible for the extended intervals between surgery and further treatment experienced by some patients. Patients typically were notified by mail to return for further therapy after lumpectomy, but indigent patients can be difficult to contact by mail, because they tend to move frequently or do not have a mailing address.

Mailings also have been delayed by inefficiencies in the hospital mailing system. “We have made efforts in recent years to decrease that time, and it has improved recently,” Dr. Burri said.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.